EP-1943: CT-guided Radioactive Seed Implantation for Locally Recurrent Rectal Cancer

Hao Wang,Fumei Yi,Junjie Wang,Huishu Yuan,Jinna Li,Yuiang Jiang,Suqing Tian

DOI: https://doi.org/10.1016/s0167-8140(15)32061-2

IF: 2.441

2014-01-01

Brachytherapy

Abstract:To evaluate the response rate, local control, overall survival, pain control rate and treatment-related toxicity of CT-guided radioactive seed implantation for locally recurrent rectal cancer (LRRC). From September 2003 to October 2011, thirty-one patients with locally recurrent rectal cancer received 125I or 103Pd seeds implantation under CT guidance in our center. Each patient underwent three-dimentional treatment planning pre-implantation and dosimetric verification post-implantion. The range of activity of seed was from 0.40 to 1.40 mCi, and the range of seeds number was from 33 to 137. The range of D90% was from 75.91 to 159.32 Gy. The followup rate was 93.5%, the median followup time was 15.7 months (4.2 ∼ 98.1 months). The response rate of pain relief was 95.2%. The overall response rate was 51.6%, in which complete response rate was 16.1% and partial response rate was 35.5%. The 1-, 2- and 3-year local control rates were 32.3%, 11.3% and 11.3%, respectively. The median local control survival was 8.0 month. The 1-, 2- and 3-year survival rates were 67.6%, 36.0% and 7.5%, respectively. The median overall survival was 21.5 months. Six patients were observed complications. CT-guided radioactive seed implantation is a minimally invasive treatment for locally recurrent rectal cancer with satisfied efficacy and tolerable complications. It is another treatment option for locally recurrent rectal cancer, especially for those with previous pelvic radiation. These findings need to be validated by conducting further studies with larger cohorts.